- Start
- Mar 31, 202690% CONFIDENCEfrom the source
Lilly Agrees to Acquire Centessa for Up to $7.8 Billion
- On 31 March 2026 Lilly and Centessa Pharmaceuticals announced a definitive agreement for Lilly to acquire Centessa, which develops orexin receptor 2 (OX2R) agonists for excessive daytime sleepiness[1][5]
- Lilly offered $38.00 in cash per share plus a contingent value right worth up to $9.00, up to $47.00 a share in total: about $6.3 billion upfront and up to $1.5 billion more, or up to $7.8 billion[1][6]
- The CVR pays $2 on FDA approval in narcolepsy type 2, $5 in idiopathic hypersomnia (each within five years of closing) and $2 on a first FDA approval in any indication before 1 January 2030[1]
- The cash price was a premium of about 40.5% to Centessa's 30-day volume-weighted average price, and about 38% to the previous day's close[1][6]
- Lead candidate cleminorexton (formerly ORX750) has shown a potential best-in-class profile in Phase 2a studies in narcolepsy type 1, narcolepsy type 2 and idiopathic hypersomnia[1]
- The deal ran as a UK scheme of arrangement: the High Court sanctioned it on 22 June 2026, and it was completed on 24 June 2026, when Centessa became a Lilly subsidiary and its ADSs left Nasdaq[2]
References 687% CONFIDENCE
The first entry is always the pin's source. Overall confidence is a weighted average of how firmly each reference supports the start and end times used above; a reference counts half as much for every 180 days older than the newest.
- [1]90%prnewswire.com/news-releases/lilly-to-acquire-centessa-pharmaceuticals-to-advance-treatments-for-sleep-wake-disorders-302729846.htmlprnewswire.com· Posted Sep 23, 2026· Starts Mar 31, 2026 ✓· 27% of score
The joint release is datelined "INDIANAPOLIS and BOSTON and LONDON, March 31, 2026" and says the companies "today announced a definitive agreement for Lilly to acquire Centessa".
- [2]90%Centessa Pharmaceuticals Form 8-K (completion of acquisition by Eli Lilly)sec.gov· Published Jun 24, 2026· 19% of score
Centessa's 8-K: the High Court sanctioned the scheme on June 22, 2026, and on June 24, 2026 the acquisition was completed and Centessa became a wholly owned Lilly subsidiary; Nasdaq trading in the ADSs was halted.[1]
- [3]80%Lilly to acquire Centessa in deal worth up to $7.8bnpmlive.com· Published Apr 10, 2026· 14% of score
PMLiVE: Lilly's deal for Centessa is worth up to $7.8bn.
- [4]80%Lilly advances neuroscience portfolio with $7.8bn acquisition of Centessaeuropeanpharmaceuticalreview.com· Published Apr 1, 2026· 14% of score
European Pharmaceutical Review: about $6.3 billion upfront plus a $1.5 billion CVR on three milestones; expected to close in Q3 2026.
- [5]92%Centessa Pharmaceuticals Form 8-K (Transaction Agreement with Eli Lilly)sec.gov· Published Mar 31, 2026· 14% of score
Centessa's 8-K filed 31 Mar 2026: the Transaction Agreement with Lilly is dated March 31, 2026, and the joint press release was issued that day.[1]
Suggest a correction
Something missing or wrong? Say it in your own words: a link that backs this pin up, a different start or end date and why, or a fact it lacks or gets wrong. The AI checks it against this pin's sources, searches for better ones, and adds any page that backs you up. The pin's own sources still count most.
